You just read:

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha(TM) (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

News provided by

Amgen

Jul 27, 2015, 05:10 ET